Browse ALMS1

Summary
SymbolALMS1
NameAlstrom syndrome protein 1
Aliases KIAA0328; Alstrom syndrome 1; ALSS
Chromosomal Location2p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Cytoplasm, cytoskeleton, cilium basal body. Cytoplasm, cytoskeleton, spindle pole. Note=Associated with centrosomes and basal bodies at the base of primary cilia. Specifically locates to the proximal ends of centrioles and basal bodies. Colocalizes partially with NCAPD2 at these sites. During mitosis localizes to both spindle poles.
Domain PF15309 ALMS motif
Function

Involved in PCM1-dependent intracellular transport. Required, directly or indirectly, for the localization of NCAPD2 to the proximal ends of centrioles. Required for proper formation and/or maintenance of primary cilia (PC), microtubule-based structures that protrude from the surface of epithelial cells.

> Gene Ontology
 
Biological Process GO:0000086 G2/M transition of mitotic cell cycle
GO:0007015 actin filament organization
GO:0007034 vacuolar transport
GO:0010927 cellular component assembly involved in morphogenesis
GO:0016197 endosomal transport
GO:0030031 cell projection assembly
GO:0030038 contractile actin filament bundle assembly
GO:0031032 actomyosin structure organization
GO:0032231 regulation of actin filament bundle assembly
GO:0032956 regulation of actin cytoskeleton organization
GO:0032970 regulation of actin filament-based process
GO:0042384 cilium assembly
GO:0043149 stress fiber assembly
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044782 cilium organization
GO:0044839 cell cycle G2/M phase transition
GO:0051017 actin filament bundle assembly
GO:0051492 regulation of stress fiber assembly
GO:0051493 regulation of cytoskeleton organization
GO:0060271 cilium morphogenesis
GO:0061572 actin filament bundle organization
Molecular Function GO:0042805 actinin binding
GO:0051393 alpha-actinin binding
Cellular Component GO:0000922 spindle pole
GO:0005813 centrosome
GO:0005814 centriole
GO:0005819 spindle
GO:0005929 cilium
GO:0031514 motile cilium
GO:0044450 microtubule organizing center part
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-8854518: AURKA Activation by TPX2
R-HSA-5620912: Anchoring of the basal body to the plasma membrane
R-HSA-1640170: Cell Cycle
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-380287: Centrosome maturation
R-HSA-5617833: Cilium Assembly
R-HSA-69275: G2/M Transition
R-HSA-380259: Loss of Nlp from mitotic centrosomes
R-HSA-380284: Loss of proteins required for interphase microtubule organization from the centrosome
R-HSA-453274: Mitotic G2-G2/M phases
R-HSA-1852241: Organelle biogenesis and maintenance
R-HSA-380270: Recruitment of mitotic centrosome proteins and complexes
R-HSA-2565942: Regulation of PLK1 Activity at G2/M Transition
Summary
SymbolALMS1
NameAlstrom syndrome protein 1
Aliases KIAA0328; Alstrom syndrome 1; ALSS
Chromosomal Location2p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ALMS1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolALMS1
NameAlstrom syndrome protein 1
Aliases KIAA0328; Alstrom syndrome 1; ALSS
Chromosomal Location2p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ALMS1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolALMS1
NameAlstrom syndrome protein 1
Aliases KIAA0328; Alstrom syndrome 1; ALSS
Chromosomal Location2p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ALMS1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.2340.176
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.2570.618
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2190.607
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.030.932
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.2470.928
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3790.913
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3740.242
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1480.912
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.6310.671
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.9970.364
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.6060.303
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0330.596
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ALMS1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141721.4021.40.081
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103200201
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 414250250.222
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.86.880.247
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.88.56.30.453
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.317.6-3.31
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.516.7-4.21
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.418.2-2.81
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382715.8015.80.037
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.6013.60.279
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161418.8018.80.228
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolALMS1
NameAlstrom syndrome protein 1
Aliases KIAA0328; Alstrom syndrome 1; ALSS
Chromosomal Location2p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ALMS1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolALMS1
NameAlstrom syndrome protein 1
Aliases KIAA0328; Alstrom syndrome 1; ALSS
Chromosomal Location2p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ALMS1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ALMS1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolALMS1
NameAlstrom syndrome protein 1
Aliases KIAA0328; Alstrom syndrome 1; ALSS
Chromosomal Location2p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ALMS1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolALMS1
NameAlstrom syndrome protein 1
Aliases KIAA0328; Alstrom syndrome 1; ALSS
Chromosomal Location2p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ALMS1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolALMS1
NameAlstrom syndrome protein 1
Aliases KIAA0328; Alstrom syndrome 1; ALSS
Chromosomal Location2p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ALMS1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolALMS1
NameAlstrom syndrome protein 1
Aliases KIAA0328; Alstrom syndrome 1; ALSS
Chromosomal Location2p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ALMS1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.